Review Claim by Claim

 Long Explanation Copied

Cross-Species Anabolic Evidence for Globin Digest

This preprint reports that orally administered globin digest (GD), an acidic protease hydrolysate of porcine hemoglobin, promotes skeletal muscle hypertrophy and motor performance in zebrafish, mice, and C2C12 myoblasts. Zebrafish fed GD (400 mg/kg BW/day, 1 week) showed 2.9-fold higher average escape acceleration, 3.8-fold higher maximum burst acceleration, 1.9-fold higher swimming speed (all p < 0.05, n = 5/group), and 1.39-fold thicker trunk muscle fibers (p < 0.01, control n = 4) GD zebrafish locomotor and histology results.

In C57BL/6J mice (0.5% GD diet, 4 weeks; n = 6 control, 7 GD), grip strength rose 14.4%, rotarod latency 1.79-fold, gastrocnemius fiber cross-sectional area 1.38-fold, and fast-twitch Myh1/Myh2 mRNA 1.90/1.77-fold (all p < 0.05), while body weight and food intake were comparable between groups—strengthening the claim that effects are muscle-specific rather than growth-related Mouse GD performance and myogenic gene data.

Peptide Relay Model and In Vitro Mechanism

In C2C12 cells, GD dose-dependently increased MyHC accumulation (1–100 µg/mL; p < 0.0001 at day 5, n = 5). Of six constituent peptides, WTQR (Pep3) and WGK (Pep5) drove early MyoD/Myf5 induction, while VVYP (Pep2) and FES (Pep6) boosted mid-stage MyHC at day 3. Notably, Myog/Myh1/Myh2 mRNA showed no significant differences at day 5 despite elevated MyHC protein—interpreted as a transcription-translation lag, though unmeasured earlier timepoints leave this assumption untested C2C12 peptide relay findings. The proposed PHT1/mTORC1 lysosomal mechanism for WTQR/WGK is entirely inferential—no direct transporter or mTORC1 blockade experiments were performed.

Critical Limitations and Blind Spots

• Conflicts of interest: Funding from Rohto Pharmaceutical, with Fukada affiliated with Rohto and Ishido employed by MG Pharma (the GD supplier)—sponsor bias and potential positive-result bias cannot be excluded.
• No intact-protein comparator: The claim that GD acts as "signaling" rather than a nitrogen source is unsupported without isonitrogenous whey/casein controls.
• Small samples: n = 4–7 per in vivo group; no sex balance (female fish, male mice only); no randomization/blinding reported.
• Missing raw values: Mostly fold-changes without SDs, CIs, or absolute values; no data availability statement.
• Relay not validated: No direct test of combined peptide cocktail vs individual peptides or whole GD—the central "synergy" claim is explicitly deferred to future work.
• Translation gap: No human data; doses in mice (1 g/kg) far exceed typical supplement exposures; no pharmacokinetics of peptide absorption in muscle.

Bottom line: Internally consistent, multi-model evidence that GD enhances myogenic markers and performance, but the signaling-vs-nutrition distinction and the peptide-relay mechanism remain hypotheses requiring isonitrogenous controls, cocktail-vs-component tests, and independent replication. Confidence: moderate for in vivo phenotypes; low for the mechanistic relay model.

 BGPT Paper Review

Study Novelty

First identification of stage-specific myogenic peptide relay (WTQR/WGK early, VVYP/FES mid) from globin digest and direct cross-species demonstration of hypertrophy—an original extension of prior GD anti-obesity work.

Scientific Quality

Multi-model consistency and matched body weight/food intake strengthen credibility, but no isonitrogenous protein control, no blinding/randomization detail, small n (4–7), no raw data/SDs, no data availability, and corporate conflicts of interest (Rohto/MG Pharma) limit quality. Relay mechanism is inferential (PHT1/mTORC1 untested).

Study Generality

Cross-species (fish, mouse, cell) framework increases generality, but effect scope is narrow (fast-twitch hypertrophy/performance in young animals) and human generalization is untested.

Study Usefulness

Directly relevant to sports nutrition and sarcopenic obesity strategies; identifies candidate peptide sequences for follow-up. Practical value is constrained by absent human efficacy/safety data and no comparison with standard protein supplements.

Study Reproducibility

Methods are described (doses, durations, assays, software), but raw values, SDs, exact statistical tests per comparison, and data/code availability are missing, hampering exact replication.

Explanatory Depth

Temporal peptide activity mapping and the proposed PHT1/mTORC1 route show mechanistic ambition, but no direct signaling assays (p-mTOR, transporter knockdown, transcriptional time-course between day 3–5) were performed to verify the relay model.